Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis.
F BärT KühbacherN A DietrichT KrauseAndreas StallmachN TeichStefan SchreiberJens WalldorfR SchmelzC BüningK FellermannJ BüningU Helwignull nullPublished in: Alimentary pharmacology & therapeutics (2017)
Our data indicate that vedolizumab could be an option in the treatment of patients with chronic, antibiotic-dependent or refractory pouchitis.